Adalimumab, Infliximab and Etanercept Biosimilars Market Expected To Reach $8.04 Billion By 2030 As Growth Accelerates At 10.1% CAGR
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Adalimumab, Infliximab and Etanercept Biosimilars Market Revenue Growth Supported By A CAGR Of 8.04% Through 2030
The market for biosimilars of adalimumab, infliximab, and etanercept has seen swift expansion in recent years. Projected figures indicate a rise from $4.96 billion in 2025 to $5.47 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.3%. This historical upward trend is driven by several factors, including a higher incidence of autoimmune conditions, the substantial expense associated with original biologic drugs, enhanced awareness surrounding biosimilars, advances in the production of biologics, and favorable policies implemented by governments.
Over the next several years, the market for adalimumab, infliximab, and etanercept biosimilars is anticipated to experience robust expansion. Projections indicate it will reach $8.05 billion by 2030, achieving a compound annual growth rate (CAGR) of 10.1%. This expected growth is fueled by progress in precision medicine, an increasing number of biosimilar pipelines, higher healthcare spending, greater uptake of digital health tools, and a growing elderly population. Key developments shaping the forecast period involve wider biosimilar acceptance and market reach, economical TNF-alpha inhibitor creation, regulatory endorsements and supportive policies, expanded distribution through hospital and retail pharmacy channels, and the adoption of tailored treatment approaches.
Download A Free Sample Report For Comprehensive Market Insights:
Adalimumab, Infliximab and Etanercept Biosimilars Market Growth Drivers: What Factors Are Accelerating Expansion?
The growth of the market for adalimumab, infliximab, and etanercept biosimilars is anticipated to be driven by the increasing incidence of autoimmune diseases. Autoimmune diseases are conditions resulting from immune system malfunction, where the body’s own healthy cells are attacked by immune cells. Adalimumab, infliximab, and etanercept are biological therapies that function as tumor necrosis factor (TNF) alpha inhibitors, commonly employed in the treatment of various autoimmune disorders. As an example, data from Johns Hopkins University, a private research institution based in the US, indicates that in 2023, approximately 10 million individuals in the United States—accounting for 3% of the population—are impacted by all forms of autoimmune diseases. Hence, the escalating prevalence of autoimmune diseases is fueling the expansion of the adalimumab, infliximab, and etanercept biosimilars market.
Adalimumab, Infliximab and Etanercept Biosimilars Market Segmentation Trends And Revenue Drivers
The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –
1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications
Subsegments:
1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others
2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others
3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development
Adalimumab, Infliximab and Etanercept Biosimilars Market Trends: What Is Shaping Future Industry Growth?
Leading firms in the adalimumab, infliximab, and etanercept biosimilars sector are prioritizing innovations like high-concentration, citrate-free biosimilars to address the growing need for patient-centric formulations, enhanced cost-effectiveness, and wider market accessibility. These advanced high-concentration, citrate-free products maintain the same therapeutic monoclonal antibody structure as standard biosimilars, yet deliver a more tolerable injection experience with less discomfort during administration, which can boost patient adherence and encourage switching from traditional buffered options. A notable example occurred in June 2023, when Celltrion USA, a US-based biopharmaceutical company, introduced Yuflyma (adalimumab-aaty), a citrate-free, high-concentration (100 mg/mL) biosimilar of Humira (adalimumab). This product is engineered to provide equivalent strength and effectiveness in a more convenient format for patients, offering the full therapeutic advantages of adalimumab while minimizing injection-related discomfort, thereby facilitating greater adoption in the immunology marketplace, especially for managing chronic inflammatory conditions.
Adalimumab, Infliximab and Etanercept Biosimilars Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the adalimumab, infliximab and etanercept biosimilars market are Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad
Access The Complete Adalimumab, Infliximab and Etanercept Biosimilars Market Report:
Adalimumab, Infliximab and Etanercept Biosimilars Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2025. The regions covered in the adalimumab, infliximab and etanercept biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
